UNSPSC 51111745: Gemtuzumab

This classification denotes an anti-cd33 immunotoxin, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8GZG754X6M. European Medicines Agency schedules Gemtuzumab ozogamicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20794. Gemtuzumab generally arises in the molecular formula C73H96IN6O25S3. The term GEMTUZUMAB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 no. 1, 2001, list 45.) Most nations schedule Gemtuzumab under HS 30021091 and SITC 54163.

SMILES:. As of Q4 2014, GEMTUZUMAB remains the US FDA Preferred Term for this commodity..

UNSPSC 51111745 Gemtuzumab, a Commodity code, does not map to the state and local contract opportunities currently tagged under it. The recent solicitations show naloxone and drug deactivation systems procurement, therapeutic pharmacy initiatives for direct-to-manufacturer prescriptions, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals and OTC products through cooperative purchasing — none of which involve gemtuzumab (an anti-CD33 monoclonal antibody used in oncology). The code's nominal scope and the actual work being bought under this tag do not align, suggesting either a miscoding issue in the underlying procurement system or minimal gemtuzumab-specific demand among state and local buyers at this time.

State and local governments are acquiring pharmaceuticals and medical supplies through a mix of county health departments, state agencies, cities, and regional cooperative purchasing alliances. Seminole County, Florida recently solicited naloxone and drug deactivation systems on an IFB basis (due July 26, 2023). The Texas Health and Human Services Commission issued an RFI on direct-to-manufacturer prescription programs (due April 3, 2026). The City of Tampa released a sheltered-market IFB for medical and first aid supplies designated for the Fire Department Rescue Division, estimated at $700,000 with a 5% SLBE discount (due March 13, 2026). The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted an RFP for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, proposals due March 26, 2026. Geographic activity spans Florida, Texas, Minnesota, and Oregon through cooperative arrangements. The mismatch between the code's stated product and the actual solicitations raises questions about whether this code is actively used for state and local pharmaceutical procurement or remains a classification artifact.